Promotes reverse cholesterol transport
Sirtuins & Nrf2 genes activates LXR & FXR, and increases the expression of Apo-A1, Promoting HDL synthesis.
-
Cardiovascular diseases (CVDs) are the leading cause of death globally, taking an estimated 17.9 million lives each year.
-
According to the World Health Organization (WHO), 39% of the world adult population has been affected by elevated blood cholesterol...
-
... with a relatively higher prevalence among women (40%) than among men (37%).
-
Despite positive secondary prevention strategies post MI, including statin use and lifestyle changes, 32% of the annual MI are recurrent.
MYOREVAL revives heart health, by upregulating SIRTUINS and Nrf2 gene
in Coronary Artery Disease.
How Myoreval may help?
Significantly upregulates SIRTUINS & Nrf2 genes and significantly decreases risk factor of CVD within first 180 days of therapy.
Decreases prevalence of myocardial infarction
Sirtuins & Nrf2 gene activation decreases MMP2 & prevents plaque rupture & degradation of collagen and elastin.
Improves vascular tone
Sirtuins & Nrf2 gene activation deacetylates eNOS , increases NO synthesis and promotes vasodilation.
Regulates rhythm of heart
Sirtuins & Nrf2 gene activation deacetylates SERCA-2a improves relaxation and contraction of cardiac muscles.
Regulates overall cardiac performance
Sirtuins & Nrf2 gene activation deacetylates PGC-1 alpha, improves contractability of heart.
Decreases cardiac hypertrophy
Sirtuin & Nrf2 gene activation regulates the kinases and decrease the cardiac hypertrophy.